In An Inorganic Compound Patents (Class 424/1.61)
  • Patent number: 9396826
    Abstract: An isotope production target may include an outer diameter wall and an inner diameter wall. An isotope source may be located between the inner diameter wall and the outer diameter wall, and the isotope source may comprise fissile material interspersed with one or more voided regions. A central region may be located within the inner diameter wall, and the central region may be configured to house a neutron thermalization volume.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: July 19, 2016
    Assignee: OREGON STATE UNIVERSITY
    Inventors: Steven Richard Reese, Todd Stephen Palmer, Stephen Todd Keller, Madicken Munk
  • Patent number: 9370554
    Abstract: Disclosed herein are compositions and methods useful for the treatment of cancer, such as breast cancer. In some embodiments, the methods and compositions include human prolactin, or human prolactin in conjunction with a cytotoxic agent. In other embodiments, the methods and compositions include one or more of human prolactin, growth hormone and placental lactogen, or one or more of human prolactin, growth hormone and placental lactogen in conjunction with a cytotoxic agent. In some embodiments, the cytotoxic agent comprises a chemotherapeutic agent.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: June 21, 2016
    Assignee: Orbis Health Solutions LLC
    Inventors: Wen Yuan Chen, Eric H. Lee
  • Patent number: 9358377
    Abstract: A low-dose-rate (LDR) brachytherapy device having a spatiotemporal radiation profile includes an elongated body having a radioactive material in a spatial pattern to provide a spatial radiation profile with a radiation intensity that varies along a length of the elongated body. The radioactive material includes at least first and second radioisotopes having at least first and second respective decay profiles that together provide a temporal radiation profile that is different from the first and second decay profiles. The spatial radiation profile and the temporal radiation profile form a net spatiotemporal radiation profile configured to provide a radiotherapy plan for a patient.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: June 7, 2016
    Assignee: Civatech Onocology
    Inventors: Robert D. Black, Jeffrey C. Leung
  • Publication number: 20150125387
    Abstract: The application describes methods for accurately evaluating whether thyroid test samples, especially indeterminate thyroid samples, are benign or malignant.
    Type: Application
    Filed: December 30, 2014
    Publication date: May 7, 2015
    Inventors: Xavier M. Keutgen, Thomas J. Fahey, III, Olivier Elemento, Rasa Zarnegar
  • Publication number: 20150118495
    Abstract: This invention relates to strontium-phosphate microparticles that incorporate radioisotopes for radiation therapy and imaging.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 30, 2015
    Applicant: MO-SCI CORPORATION
    Inventors: Delbert E. Day, Yiyong He
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Publication number: 20150104386
    Abstract: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and v) eluting the 223Ra from said strong acid cation exchange resin losing a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.
    Type: Application
    Filed: November 20, 2014
    Publication date: April 16, 2015
    Inventors: Jan Roger KARLSON, Peer BØRRETZEN
  • Publication number: 20150064108
    Abstract: A method of preparing radioisotope hybrid nanocomposite particles using a sol-gel reaction, and radioisotope hybrid nanocomposite particles prepared using the same are provided. The method includes preparing a complex precursor using a metal ion and an unshared electron pair reactive compound, growing hybrid nanocomposite particles based on the complex precursor by means of a sol-gel reaction, calcining the nanocomposite particles in the air to remove organic matters present in the nanocomposite particles, and irradiating the nanocomposite particles with neutrons to prepare radioisotope hybrid nanocomposite particles. The radioisotope nanocomposite particles prepared using the method can be used as diagnostic and therapeutic particles in the fields of oil refining, chemistry, cement, agriculture, water resources, environment, ocean, and medicine, and can also be used as a radioisotope tracer for evaluating the risk of nanomaterials.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Inventors: Sung-Hee Jung, Sun Ju Choi, Jong Bum Kim, Jin Ho Moon, Seong Ho Choi, Sang Ei Seo
  • Patent number: 8961926
    Abstract: The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: February 24, 2015
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Walter Anthony Henne, Jr., Bindu Varghese, Ryan Rothenbuhler
  • Patent number: 8952057
    Abstract: Compositions containing polymetal complexes are useful in treating anorectal disorders.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: February 10, 2015
    Assignee: JR Chem, LLC
    Inventor: José E. Ramirez
  • Patent number: 8911705
    Abstract: The present invention relates to a diagnostic substance, containing at least one complex of lipophilic anions and metal ions, wherein the lipophilic anions are selected from the group comprising: triethylene tetramine dihydrochloride (TETA), ethyl cysteinate dimer (ECD), methoxyisobutylisonitrile (MIBI), HMPAO (d,l-hexamethylpropylene aminoxime), ethylenediamine N,N,N?,N?-tetraacetanilide (EDTAN), dimethyldithiocarbamate (DMC) and diethyldithiocarbamate (DDC) and glycine N,N?-[1,2-ethanediylbis(oxy-2,1-phenylene)]bis [N-(carboxymethyl)-1,1?-bis[2-(octadecyloxy)ethyl]ester (DP-109), and wherein the metal ions are selected from the group comprising thallium isotopes, lead isotopes, cobalt isotopes and manganese isotopes, together with solvents, adjuvants and/or vehicles. The diagnostic substance is used for investigating metabolic processes in the brain and/or central nervous system (CNS).
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: December 16, 2014
    Assignee: Leibniz-Institut fuer Neurobiologie Stiftung des Oeffentlichen Rechts
    Inventors: Iryna Ziabreva, Petra Henrich-Noack, Juergen Goldschmidt, Kathrin Baldauf, Henning Scheich, Klaus G. Reymann, Ulrich H. Schroeder, Claudia Pforte, Monika Riek-Burchardt
  • Publication number: 20140356282
    Abstract: Methods of synthesizing 100Mo2C and 99mTcO4? are disclosed. Methods of 100Mo2C generation involve thermally carburizing 100MoO3. Methods of 99mTcO4 generation involve proton bombardment of 100Mo2C in a cyclotron. Yields of 99mTcO4 can be increased by sintering 100Mo2C prior to bombardment. The methods also include recycling of 100Mo2C to form 100MoO3. SPECT images obtained using 99mTcO4 generated by the disclosed methods are also presented.
    Type: Application
    Filed: June 2, 2014
    Publication date: December 4, 2014
    Applicant: Washington University
    Inventors: Vernal Richards, Suzanne Lapi
  • Publication number: 20140341803
    Abstract: Described herein are methods for treating a tumor or cancer in a subject. The methods involve administering to the subject a nanoemulsion comprising (1) at least one perfluoro crown ether and (2) a block copolymer comprising a hydrophilic block and hydrophobic block, wherein the hydrophobic block is poly(d,l)lactic acid, and wherein the nanoemulsion comprises a therapeutic agent encapsulated in the nanoemulsion. The methods do not require the application of ultrasound or other sources of radiation in order to treat a tumor or cancer in the subject.
    Type: Application
    Filed: May 14, 2014
    Publication date: November 20, 2014
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Natalya Rapoport
  • Publication number: 20140335017
    Abstract: This invention relates to strontium-phosphate microparticles that incorporate radioisotopes for radiation therapy and imaging.
    Type: Application
    Filed: September 16, 2010
    Publication date: November 13, 2014
    Inventors: Delbert E. Day, Yiyong He
  • Patent number: 8865123
    Abstract: This invention relates to strontium-phosphate microparticles that incorporate radioisotopes for radiation therapy and imaging.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: October 21, 2014
    Assignee: MO-SCI Corporation
    Inventors: Delbert E. Day, Yiyong He
  • Publication number: 20140308342
    Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.
    Type: Application
    Filed: November 7, 2012
    Publication date: October 16, 2014
    Inventors: David A. Spiegel, Charles E. Jakobsche
  • Publication number: 20140199236
    Abstract: Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 17, 2014
    Applicant: ARAGON PHARMACEUTICALS, INC.
    Inventors: ISAN CHEN, JEFFREY H. HAGER, EDNA CHOW MANEVAL, MARK R. HERBERT, NICHOLAS D. SMITH
  • Publication number: 20140193335
    Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: ENIGMA THERAPEUTICS LIMITED
    Inventors: Roger ASTON, Leigh T. CANHAM
  • Patent number: 8772226
    Abstract: Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific antigen (PSA), prostate specific membrane antigen (PSMA) or human glandular kallikrein (hK2). Various further embodiments relate more specifically to PSMA-specific peptide prodrugs that become activated to yield therapeutic drugs. Further aspects of various embodiments of the present invention also relate to methods and compositions for treating or preventing cancers and methods and compositions for detecting and/or imaging cancers.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: July 8, 2014
    Assignee: The Johns Hopkins University
    Inventors: Samuel Ray Denmeade, John Tod Isaacs, Soeren Brogger Christensen
  • Patent number: 8753609
    Abstract: A standardized, edible food containing a label for use in the measurement of gastric emptying by the quantification of marker excreted in the breath of the patient and methods of making the same using fluid bed granulation processing.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: June 17, 2014
    Assignee: Advanced Breathe Diagnostics, LLC
    Inventors: Kerry C. Bush, Stanley J. Konopka, Ronald W. Sanda
  • Publication number: 20140134104
    Abstract: The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumour or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumour or other lesion.
    Type: Application
    Filed: April 18, 2012
    Publication date: May 15, 2014
    Applicant: DSPI LTD.
    Inventor: Peter Knox
  • Patent number: 8709380
    Abstract: Targeting agents are provided that have an affinity for aberrant cells and tissues. These agents are comprised of chelates, ligands, and/or particles combined with high atomic weight elements so that treatment with ionizing electromagnetic radiation (X-rays, or Gamma rays) results in a higher dose to aberrant cells and tissues than other cells and tissues of a host. The invention further provide methods to enhance the tumor to normal tissue damage ratio by concentrating agents with high atomic number elements to the site of the tumor prior to administering radiotherapy. The result is greater therapeutic efficacy with fewer side effects. These compounds also permit diagnostic uses in combination with the therapeutic use.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: April 29, 2014
    Assignee: Sirius Medicine, LLC
    Inventors: Michael D. Weil, Kevin N. Morris, Rainer M. Malzbender
  • Publication number: 20140099261
    Abstract: The application describes methods for accurately evaluating whether thyroid test samples, especially indeterminate thyroid samples, are benign or malignant.
    Type: Application
    Filed: September 20, 2013
    Publication date: April 10, 2014
    Applicant: Cornell University
    Inventors: Xavier M. Keutgen, Thomas J. Fahey, III, Olivier Elemento, Rasa Zarnegar
  • Publication number: 20140093451
    Abstract: Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Inventor: Lawrence Richard Bernstein
  • Publication number: 20140079630
    Abstract: The invention provides compositions and methods for visualizing particular tissues and delivering one or more therapeutics to that tissue using single-walled carbon nanotubes (SWNTs), which are taken up and delivered to target tissues by specific monocytes in the body. The delivery of SWNT to target tissues allows the visualization of the affected tissue for diagnostics and therapy in diseases where the specific monocyte is implicated in the disease pathogenesis. These nanotubes can be conjugated to a peptide, such as RGD, which helps direct the SWNT-containing monocytes to the vascular endothelium.
    Type: Application
    Filed: September 7, 2013
    Publication date: March 20, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Bryan R. Smith, Eliver Ghosn
  • Patent number: 8632748
    Abstract: Compositions of high specific activity 117mSn with specific activity of greater than 100 Ci/g Sn and methods of producing the same. The method includes exposing 116Cd to an ?-particle beam of sufficient incident kinetic energy and duration to convert a portion of the 116Cd to 117mSn to form an irradiated material. The irradiated material is dissolved to form an intermediate solution containing 117mSn and 116Cd. The 117mSn is separated from the 116Cd to yield high specific activity 117mSn.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: January 21, 2014
    Assignee: Clear Vascular, Inc.
    Inventors: Nigel Raymond Stevenson, Ian Martin Horn
  • Publication number: 20130343988
    Abstract: The invention is directed to Compounds of Formula (I). The invention provides compounds that inhibit, regulate, and/or modulate P13K that are useful in the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: January 3, 2013
    Publication date: December 26, 2013
    Applicant: Exelixis, Inc.
    Inventor: Exelixis, Inc.
  • Publication number: 20130302244
    Abstract: The present invention provides a technique for adsorbing I-125 on a support for treating cancer and a method of preparing an I-125 seed using the same. Since a method of preparing iodine according to the present invention uses an intermediate having phosphate-based, oxalate-based, or arsenate-based anions introduced thereinto, the intermediate has a substitution effect of iodine 3 to 5 times higher than that of a typically used intermediate having chlorine anions introduced thereinto. According to the substitution effect, control of a radiation dose may be possible during the manufacturing of an iodine seed and an iodine seed may be prepared within a shorter period of time. Also, since an amount of residual radioactive iodine may be decreased as a result of a large amount of adsorption, an amount of radioactive iodine (I-125) waste may be decreased, and the effect thereof may be also high environmentally.
    Type: Application
    Filed: February 12, 2013
    Publication date: November 14, 2013
    Applicant: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
    Inventor: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
  • Patent number: 8557222
    Abstract: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: October 15, 2013
    Assignee: Avid Radiopharmaceuticals, Inc.
    Inventors: Franz F. Hefti, Daniel M. Skovronsky, Alan P. Carpenter, Jr.
  • Patent number: 8545808
    Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: October 1, 2013
    Assignee: Navidea Biopharmaceuticals, Inc.
    Inventors: Gerald Ross Magneson, Richard Cushman Orahood
  • Publication number: 20130251631
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 26, 2013
    Applicants: Forschungsverbund Berlin E.V., The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
  • Publication number: 20130230458
    Abstract: The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents.
    Type: Application
    Filed: September 1, 2011
    Publication date: September 5, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Randall King, Xing Zeng
  • Publication number: 20130224112
    Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
    Type: Application
    Filed: March 29, 2013
    Publication date: August 29, 2013
    Applicant: Searete LLC
    Inventor: Searete LLC
  • Patent number: 8501154
    Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: August 6, 2013
    Assignee: The Governors of the University of Alberta
    Inventors: Chris Cheeseman, Frederick West, Tina Grant, Brendan Trayner, John Mercer, Andrei Manolescu
  • Publication number: 20130136690
    Abstract: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and v) eluting the 223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.
    Type: Application
    Filed: April 29, 2011
    Publication date: May 30, 2013
    Applicant: ALGETA ASA
    Inventors: Jan Roger Karlson, Peer Børretzen
  • Publication number: 20130095034
    Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods.
    Type: Application
    Filed: November 27, 2012
    Publication date: April 18, 2013
    Applicant: IMMUNOMEDICS INC.
    Inventor: Immunomedics Inc.
  • Publication number: 20130090513
    Abstract: The present invention provides a boron drug for boron neutron capture therapy for liver cancer, which is an aqueous solution of boric acid.
    Type: Application
    Filed: February 23, 2012
    Publication date: April 11, 2013
    Applicant: National Tsing Hua University
    Inventors: Fong-in CHOU, Sy-Yu Lin, Hong-Ming Liu, Jinn-Jer Peir, Hsiao-Ping Chung
  • Patent number: 8414866
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: April 9, 2013
    Assignee: GE Healthcare AS
    Inventors: Morten Eriksen, Geir Torheim
  • Patent number: 8388936
    Abstract: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: March 5, 2013
    Assignee: MCW Research Foundation, Inc.
    Inventors: Balaraman Kalyanaraman, Joy Joseph, Kathleen Marie Schmainda, Douglas Edward Prah, Marcos Lopez, Micael J. Hardy
  • Patent number: 8388931
    Abstract: 99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 5, 2013
    Inventors: Marcos Lopez, Micael Joel Hardy, Balaraman Kalyanaraman, Ming Zhao
  • Publication number: 20130052131
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a nanoparticle, methods of imaging a tumor, method of imaging a disease, method of treating a condition, disease, or related biological event, or the like.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Zhen Cheng, Kai Cheng
  • Publication number: 20130052129
    Abstract: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.
    Type: Application
    Filed: August 27, 2012
    Publication date: February 28, 2013
    Applicant: The General Hospital Corporation
    Inventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
  • Publication number: 20130022541
    Abstract: Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.
    Type: Application
    Filed: July 18, 2012
    Publication date: January 24, 2013
    Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITY
    Inventors: Lapo Alinari, Robert A. Baiocchi, Natarajan Muthusamy, Hans J. Hansen, David M. Goldenberg
  • Publication number: 20130004418
    Abstract: The invention relates to an infiltration solution of a radiopaque metal compound for treating an enamel lesion, to a kit for dental application, and to the use thereof for preventing and/or treating (sealing) carious enamel lesions.
    Type: Application
    Filed: February 17, 2011
    Publication date: January 3, 2013
    Applicant: ERNST MUHLBAUER GMBH & CO. KG
    Inventors: Swen Neander, Thomas Konig, Stephan Neffgen, Sebastian Paris, Hendrik Meyer-Luckel
  • Publication number: 20120315217
    Abstract: TSHR inverse agonists and neutral antagonists that are useful for treating Graves' orbitopathy, Graves' hyperthyroidism and/or thyroid cancer.
    Type: Application
    Filed: April 8, 2011
    Publication date: December 13, 2012
    Inventors: Marvin Gershengorn, Susanne Neumann, Wenwei Huang, Craig J. Thomas
  • Patent number: 8317718
    Abstract: Methods for assessing an overall digestive health of a patient are provided, which include administering a breath test that uses a label incorporated into proteins, carbohydrates, and lipids and further incorporating the labeled material into a meal which, when cooked, facilitates the binding of the label material to the solid phase matrix of the meal. Methods for assessing digestive functions of a patient are also provided, which includes concurrently administering a breath test and a scintigraphy test that measure gastric emptying in a stomach.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: November 27, 2012
    Assignee: Advanced Breath Diagnostics, LLC
    Inventors: Kerry C. Bush, Robert F. Martin
  • Publication number: 20120282179
    Abstract: Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or N.
    Type: Application
    Filed: August 6, 2010
    Publication date: November 8, 2012
    Applicant: Exelixis, Inc.
    Inventors: Dana T. Aftab, Thomas Mueller, Aaron Weitzman, Jaymes Holland
  • Patent number: 8303931
    Abstract: The present invention pertains to a three compartment structured polymer nanoparticle (core-shell-corona) for multimodal imaging with specificity for cells or cellular components, thus enabling more advanced diagnostic approaches and targeted therapy on the cellular level without the use of additional biologically active materials.
    Type: Grant
    Filed: February 19, 2007
    Date of Patent: November 6, 2012
    Assignee: TOPASS GmbH
    Inventors: Ulrich Pison, Bernd-Reiner Paulke, Silvia Pietschmann, Regis Cartier, Lutz Kaufner
  • Publication number: 20120276004
    Abstract: Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating CD33+/HLA-DRlow, CD1430 /HLA-DRlow, CD66b+/HLA-DRlow or, CD11b+/HLA-DRlow MDSC for activation of a transcription factor. Transcription factors include, but are not limited to, STAT3, pSTAT3, HIF1?, or C/EBP?. The MDSC phenotype can be CD33+HLA-DRlowHIF1?+/STAT3+, CD14+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD66b+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD33+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD11b+HLA-DRlow HIF1?+/STAT3+/pSTAT3+/C/EBPb+, or CD11b+HLA-DRlowC/EBP?+. Also provided herein are methods for inducing human MDSC from healthy donor peripheral blood mononuclear cells (PBMC) by co-culturing PBMC with human solid tumor cell lines and subsequently measuring their suppressive ability.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Inventors: Alan L. Epstein, Melissa G. Lechner
  • Publication number: 20120276003
    Abstract: The present disclosure relates to a compound comprising an oxygen-15 and a process for preparation thereof. It also relates to the use of the compound in positron and/or other nuclide imaging and use of the compound in obtaining a perfusion and/or metabolic image in an animal and/or human body. A process for preparing the compound comprises irradiating a compound comprising oxygen via irradiation energy in the range of 10 MeV to 430 MeV. The oxygen atom in the compound may then be allowed to be converted to an oxygen-15 positron nuclide through a photonuclear reaction. Provided that the molecular structure of the irradiated compound is not disrupted, a compound comprising an oxygen-15 is prepared.
    Type: Application
    Filed: September 25, 2011
    Publication date: November 1, 2012
    Applicant: Beijing Top Grade Medical Equipment Co., Ltd.
    Inventors: Jun Zeng, Qiyin Sun